Contrasting Enovis (NYSE:ENOV) and P3 Health Partners (NASDAQ:PIII)

P3 Health Partners (NASDAQ:PIII) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Risk and Volatility

P3 Health Partners has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Earnings & Valuation

This table compares P3 Health Partners and Enovis”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46 billion	0.06	-$147.95 million	($38.60)	-0.29
Enovis	$2.25 billion	0.72	-$1.18 billion	($19.88)	-1.41

P3 Health Partners has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for P3 Health Partners and Enovis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1	2	1	0	2.00
Enovis	2	0	7	1	2.70

P3 Health Partners currently has a consensus price target of $14.00, indicating a potential upside of 26.01%. Enovis has a consensus price target of $41.71, indicating a potential upside of 48.84%. Given Enovis’ stronger consensus rating and higher possible upside, analysts plainly believe Enovis is more favorable than P3 Health Partners.

Insider and Institutional Ownership

7.7% of P3 Health Partners shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 10.9% of P3 Health Partners shares are held by insiders. Comparatively, 2.9% of Enovis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares P3 Health Partners and Enovis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-8.57%	N/A	-19.99%
Enovis	-49.92%	10.32%	4.57%

Summary

Enovis beats P3 Health Partners on 10 of the 15 factors compared between the two stocks.

About P3 Health Partners

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.